Lupin Pharmaceutical (NSE:LUPIN) said last week that it inked a licensing agreement with MonoSol Rx to develop pediatric products using MonoSol’s drug-delivery technology.
Warren, N.J.-based MonoSol touts its dissolvable film, PharmaFilm, as a quick-dissolving system that’s easy to administer and masked by taste. The sublingual film is designed to support pediatric populations that often have trouble swallowing pills or tolerating more invasive delivery forms.
MonoSol has 2 FDA-approved products on the market using the PharmaFilm technology – Suboxone, for treating opioid dependence, and Zuplenz anti-nausea film.
Lupin hopes to expand into specialty pharmaceutical markets, particularly pediatric needs such as attention-deficit/hyper-activity disorder, according to the Baltimore, Md.-based company.
“We believe PharmFilm technology holds great promise for pediatric applications – enabling increased compliance and adherence in a difficult to treat population,” MonoSol Rx CEO Keith Kendall said in prepared remarks. “By partnering with Lupin, whose commitment to support and expand within the pediatric and family-focused market matches our own commitment to helping pediatric patients and their families, we are taking a critical step forward in developing valuable and much-needed products.”
“At Lupin, we are motivated by addressing urgent, unmet medical needs – and helping children and their families ensure they are able to access, tolerate and successfully take the medicines they need is a clear part of that mission,” added Lupin president Paul McGarty. “Our alliance with MonoSol Rx will enable us to expand our family of pediatric products to help meet the needs of children for a variety of indications. We look forward to working with MonoSol Rx on the development of these products.”
